Bayer's recent agreement with the Dutch biotech Zilip-Pharma to develop a longer acting version of its haemophilia A treatment, Kogenate#174; (recombinant antihaemophilic factor VIII), makes considerable sense given that novel approaches to tackle the disease are to be found very early on in the development pipeline. This feature considers why the deal is good news for both parties.